BioTech & SmartPharma
APPLICATIONS OPEN : March 2022
This program accelerates ambitious startups that develop and deploy therapies based on biotechnologies.
Recent scientific discoveries are taking the biotechnology sector to new levels and into new territories. However, this also creates far-reaching challenges relating to ethics, innovation and regulations. BioTechs are revolutionizing R&D for new therapies and therapeutic processes for caregivers and patients. These solutions have the potential to transform the entire health chain – production, delivery and monitoring – and connect the scientific world to evolving economic realities.
Innovation stakes
- New therapies
- Research aid
- Personalized medicine
- Genetics
- Drug safety
- Clinical trial
- Drug discovery
- Production
These companies were accelerated by our program BioTech & SmartPharma
A few words from our entrepreneurs
“WILCO allowed us to build a network of biotech entrepreneurs and experts. In our sector, it’s important to move quickly and solve issues others have already encountered. WILCO also helped us structure ourselves and raise funds with investors to take our first treatment for cancer into clinical trials.
“
Founder & CEO
A few words from our large companies
Finance Director & Innovation Manager
“Working with WILCO makes it easier for us to monitor new developments in the health sector. By teaming up with early-stage startups, we can establish numerous win-win collaborations that offer unlimited limitless opportunities, while also being intellectually enriching. Everyone we work with at WILCO is intelligent, caring and professional.
“
These Midcaps / Large Groups are innovating with our startups in BioTech & SmartPharma
Previous
Next
Eager to create synergies with the rising stars of this ecosystem?
Our entrepreneur mentors for the program BioTech & SmartPharma
Joël Crouzet
Olivier Delaunay
Anne Rein
Alain Clergeot
Jean-Marc Josse
Our entrepreneur mentors share their experiences
WILCO Mentor
” After diverse roles in the Executive Management of international firms and smaller structures like biotechs, I supported various Deeptech startups and scaleups as the Director of Genopole Entreprises. Today I use this experience to help startups navigate the health innovation ecosystem during the different stages of standardization and growth. Above all, I help them meet the right players at the right moment and find solutions to their challenges so they can reach their first million in revenue.
“